Digest Network Come funziona
Network
/
Società
Me
Non verificato

Meiji Seika Pharma Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaSalute

12 comunicati stampa

Guarda tutti i comunicati
29/05/2026
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Volontariato/Solidarietà/Non profit
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
15/05/2026
Industria
Salute
Comunicazione
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Libri/Editoria
Biotecnologia
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
15/04/2026
Eventi
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
08/04/2026
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Meiji Pharma Asia Commences Operations in Singapore
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
30/03/2026
Industria
Oncologia
Assistenza all'Infanzia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
12/03/2026
Mercato del lavoro
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Università
Farmaceutica
Salute
Scuola/Istruzione
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
03/03/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
 Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
19/12/2025
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
03/12/2025
Salute
HIV, AIDS e malattie autoimmuni
Industria
Farmaceutica
Biotecnologia
Mercato del lavoro
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0
10/01/2025
Mercato del lavoro
Associazioni/Professionisti
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy
Fonte
Meiji Seika Pharma Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0